Maintenance immunotherapy by repetitive low-dose donor lymphocytes infusions in a child with relapse state AML after allogeneic stem cell transplantation

Pediatric Hematology and Oncology

Volumn 24, Issue 2, 2007, Pages 137-140

  Hartwig, M ^a   Weigel, S ^a   Bernig, T ^a   Bader, P ^b   Dolken R ^a   Beck, J ^a  

^a UNIVERSITY OF GREIFSWALD   (Germany)

^b GOETHE UNIVERSITY   (Germany)

Author keywords

Acute myeloid leukemia; Allogeneic stem cell transplantation; Donor lymphocyte infusion; Mixed chimerism

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTARABINE; ETOPOSIDE; IDARUBICIN; LYMPHOCYTE ANTIBODY; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; TIOGUANINE;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CASE REPORT; CD34 SELECTION; CHEMOTHERAPY; DONOR LYMPHOCYTE INFUSION; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOPOIESIS; HUMAN; IMMUNOTHERAPY; LOW DRUG DOSE; PRESCHOOL CHILD; QUALITY OF LIFE;

BLOOD DONORS; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; FEMALE; GRAFT VS HOST DISEASE; HUMANS; IMMUNOTHERAPY; INFANT; LEUKEMIA, MYELOCYTIC, ACUTE; LYMPHOCYTE TRANSFUSION; NEOPLASM RECURRENCE, LOCAL; STEM CELL TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 34247173944     PISSN: 08880018     EISSN: 15210669     Source Type: Journal    
DOI: 10.1080/08880010601125443     Document Type: Article

References (9)

1. Creutzig U, Ritter J, Zimmermann M, Schellong G. Does cranial irradiation reduce the risk for bone marrow relapse in acute myelogenous leukaemia? Unexpected results of the childhood. AML Study BFM-87. J Clin Oncol. 1993;11:279-286.
2. Béhar C, Suciu S, Benoit Y, et al. Mitoxantrone-containing regimen for treatment of childhood acute leuakemia (AML) and analysis of prognostic factors: results of the EORTC Children Leukaemia Cooperative Study 58872. Med Pediatr Oncol. 1996;26:173-179.
3. Bader P, Kreyenberg H, Hoelle W, et al. Increasing mixed chimerism is an important prognostic factor for adverse outcome in children with ALL after allogeneic SCT: possible role for preemptive immunotherapy?. J Clin Oncol. 2004;22:1696-1705.
4. Bader P, Kreyenberg H, Hoelle W, et al. Increasing mixed chimerism defines a high-risk subgroup of childhood acute myelogenous leukaemia patients after allogeneic stem cell transplantation where pre-emptive immunotherapy may be effective. Bone Marrow Transplant. 2004;33:815-821.
5. Bosi A, Laszlo D, Labopin M, et al. Second allogeneic bone marrow transplantation in acute leukaemia: results of a survey by the European Cooperative Group for Blood and Marrow Transplantation. J Clin Oncol. 2001;19:3675-3684.
6. Radich JP, Sanders JE, Buckner CD, et al. Second allogeneic marrow transplantation for patients with recurrent leukaemia after initial transplant with total-body irradiation-containing regimens. J Clin Oncol. 1993;11:304-313.
7. Collins RH, Shpilberg O, Groboyski WR, et al. Donor leukocyte infusions in 1401 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol. 1997;15:433-444.
8. Shiobara S, Nakao S, Ueda M, et al. Donor leukocyte infusion for Japanese patients with relapsed leukaemia after allogeneic bone marrow transplantation: lower incidence of acute graft-versus-host disease and improved outcome. Bone Marrow Transplant. 2000;26:809-810.
9. Carlens S, Remberger M, Aschan J, et al. The role of disease stage in the response to donor lymphocyte infusions as treatment for leukemic relapse. Biol Blood Marrow Transplant. 2001;7:31-38.